ValuEngine Downgrades Intersect ENT (NASDAQ:XENT) to Hold

ValuEngine downgraded shares of Intersect ENT (NASDAQ:XENT) from a buy rating to a hold rating in a report issued on Monday, February 4th.

Other research analysts also recently issued reports about the company. BidaskClub upgraded Intersect ENT from a sell rating to a hold rating in a report on Thursday, October 11th. Zacks Investment Research downgraded Intersect ENT from a buy rating to a hold rating in a research note on Tuesday, January 22nd. Northland Securities reiterated a hold rating and set a $28.00 target price on shares of Intersect ENT in a research note on Monday, November 5th. Finally, TheStreet downgraded Intersect ENT from a c- rating to a d+ rating in a research note on Thursday, January 3rd. Three analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of Buy and an average target price of $37.40.

Intersect ENT stock traded up $0.41 during mid-day trading on Monday, hitting $34.40. The stock had a trading volume of 266,212 shares, compared to its average volume of 288,856. Intersect ENT has a 12 month low of $25.09 and a 12 month high of $42.95. The stock has a market cap of $1.06 billion, a price-to-earnings ratio of -45.26 and a beta of 0.61.

Intersect ENT (NASDAQ:XENT) last released its quarterly earnings results on Monday, February 25th. The medical equipment provider reported ($0.16) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.16). The company had revenue of $32.80 million for the quarter, compared to analyst estimates of $32.68 million. Intersect ENT had a negative return on equity of 17.62% and a negative net margin of 20.00%. Intersect ENT’s revenue was up 11.2% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.11) earnings per share. Research analysts predict that Intersect ENT will post -0.88 earnings per share for the current fiscal year.

In other Intersect ENT news, insider Lisa D. Earnhardt sold 20,000 shares of the company’s stock in a transaction dated Monday, December 17th. The stock was sold at an average price of $29.73, for a total value of $594,600.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 5.90% of the stock is owned by insiders.

Several institutional investors have recently modified their holdings of XENT. HealthCor Management L.P. raised its stake in shares of Intersect ENT by 53.7% in the third quarter. HealthCor Management L.P. now owns 1,950,000 shares of the medical equipment provider’s stock worth $56,063,000 after purchasing an additional 681,150 shares during the last quarter. BlackRock Inc. grew its holdings in shares of Intersect ENT by 19.2% in the second quarter. BlackRock Inc. now owns 2,310,110 shares of the medical equipment provider’s stock valued at $86,515,000 after acquiring an additional 371,831 shares in the last quarter. Point72 Asset Management L.P. bought a new position in shares of Intersect ENT in the third quarter valued at approximately $9,230,000. Bamco Inc. NY grew its holdings in shares of Intersect ENT by 305.5% in the third quarter. Bamco Inc. NY now owns 393,336 shares of the medical equipment provider’s stock valued at $11,308,000 after acquiring an additional 296,336 shares in the last quarter. Finally, First Light Asset Management LLC grew its holdings in shares of Intersect ENT by 126.9% in the third quarter. First Light Asset Management LLC now owns 517,121 shares of the medical equipment provider’s stock valued at $14,867,000 after acquiring an additional 289,238 shares in the last quarter. 92.04% of the stock is owned by hedge funds and other institutional investors.

Intersect ENT Company Profile

Intersect ENT, Inc, a drug delivery company, researches and develops products for the treatment of patients with ear, nose and throat conditions in the United States. It offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses.

Recommended Story: The basics of gap trading strategies

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Intersect ENT (NASDAQ:XENT)

Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.